TLR4 and Sepsis: Among these inhibitors, the TLR4 inhibitor TAK—242 exhibits promise in the treatment of inflammatory diseases, including sepsis and acute lung injury, by obstructing the LPS—or HMGB1—mediated signaling pathways.